178 related articles for article (PubMed ID: 15803999)
1. [Evaluation of the effects of treatment of osteoporosis].
Christensen PM; Sørensen HA; Vestergaard P
Ugeskr Laeger; 2005 Feb; 167(9):1031-3. PubMed ID: 15803999
[No Abstract] [Full Text] [Related]
2. [Therapy of osteoporosis. Risk factors alone are not an indication].
MMW Fortschr Med; 2001 Dec; 143(49-50):57. PubMed ID: 11813710
[No Abstract] [Full Text] [Related]
3. [Osteoporosis. Fracture as alarm signal].
MMW Fortschr Med; 2001 Oct; 143(41):56. PubMed ID: 11721665
[No Abstract] [Full Text] [Related]
4. Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women.
Can Fam Physician; 2003 Apr; 49():487. PubMed ID: 12729244
[No Abstract] [Full Text] [Related]
5. [Patients' and population's knowledge of osteoporosis].
Ryg J; Nissen N; Nielsen D; Brixen KT
Ugeskr Laeger; 2005 Jan; 167(3):282-5. PubMed ID: 15704797
[No Abstract] [Full Text] [Related]
6. [Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
MMW Fortschr Med; 2007 Mar; 149(13):50. PubMed ID: 17672400
[No Abstract] [Full Text] [Related]
7. [Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Kruse HP
MMW Fortschr Med; 2001 Nov; 143(47):33-6. PubMed ID: 11791359
[No Abstract] [Full Text] [Related]
8. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093
[No Abstract] [Full Text] [Related]
9. Targeting high-risk populations.
Jönsson B
Osteoporos Int; 1998; 8 Suppl 1():S13-6. PubMed ID: 9682791
[No Abstract] [Full Text] [Related]
10. Evidence-based assessment of pharmaceutical interventions.
Melton LJ
Osteoporos Int; 1998; 8 Suppl 1():S17-21. PubMed ID: 9682792
[No Abstract] [Full Text] [Related]
11. [A new bisphosphonate. A vertebral body fracture seldom remains alone].
MMW Fortschr Med; 2000 Jul; 142(26-27):55. PubMed ID: 10929492
[No Abstract] [Full Text] [Related]
12. [Bisphosphonates in osteoporosis. Significantly reduces risk of fracture].
MMW Fortschr Med; 2001 May; 143(18):53. PubMed ID: 11393183
[No Abstract] [Full Text] [Related]
13. [Optimizing treatment of osteoporosis. Rapidly effective therapy lowers fracture risk in 1 year up to 70%].
MMW Fortschr Med; 2001 Sep; 143(35-36):50. PubMed ID: 11584531
[No Abstract] [Full Text] [Related]
14. [Risedronate now also approved for hip fractures. Study discloses significant risk reduction in proximal femoral neck fractures].
MMW Fortschr Med; 2001 Sep; 143(35-36):51. PubMed ID: 11584532
[No Abstract] [Full Text] [Related]
15. Screening and treatment in the elderly to reduce osteoporotic fracture risk.
Black DM
Br J Obstet Gynaecol; 1996 May; 103 Suppl 13():2-7; discussion 7-8. PubMed ID: 8624337
[No Abstract] [Full Text] [Related]
16. [Prevention of osteoporosis].
Dambacher MA; Kissling R; Neff M
Ther Umsch; 1998 Nov; 55(11):702-11. PubMed ID: 9865147
[TBL] [Abstract][Full Text] [Related]
17. [HIP study--how to prevent hip fractures?].
Itabashi A
Nihon Rinsho; 2007 Nov; 65 Suppl 9():286-92. PubMed ID: 18159711
[No Abstract] [Full Text] [Related]
18. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between studies and general practice].
MMW Fortschr Med; 2006 Nov; 148(46):49. PubMed ID: 17615791
[No Abstract] [Full Text] [Related]
20. [Osteoporosis-induced fractures. Bisphosphonates lower risk also in the hip].
MMW Fortschr Med; 2000 Jul; 142(30):52-3. PubMed ID: 10955025
[No Abstract] [Full Text] [Related]
[Next] [New Search]
